Deltanoid Pharmaceuticals Inc.

Two years after Amgen acquired KAI Pharmaceuticals and its drug for hyperparathyroidism in chronic kidney disease (CKD), the Thousand Oaks, California-based biotechnology company is reporting statisti

Modifying the vitamin D molecule to enhance its bone building activity 645 Science Drive, Madison, WI 53711 Phone: (608) 238-7710 Fax: (608) 238-7715 Web Site: www.deltanoid.com Contact: Hector F. D

Significant increases in the drug-treated patient population push start-ups to pursue novel mechanisms of action for treating osteoporosis. Osteoporosis, a disease characterized by low bone mass and s

A preview of the emerging health care companies profiled in the current issue of START-UP: Windhover's Review of Emerging Medical Ventures This month's profile groups: Salve for the Wound Care Market